Publicaciones en colaboración con investigadores/as de Medical University of South Carolina (61)

2024

  1. A plain language summary of publication of the efficacy and safety of individualized niraparib dosing based on baseline body weight and platelet count in the PRIMA/ENGOT-OV26/GOG-3012 trial

    Future oncology (London, England), Vol. 20, Núm. 13, pp. 799-809

  2. A plain language summary of publication of the efficacy and safety of individualized niraparib dosing based on baseline body weight and platelet count in the PRIMA/ENGOT-OV26/GOG-3012 trial

    Future Oncology, Vol. 20, Núm. 13, pp. 799-809

  3. Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial

    Gynecologic Oncology, Vol. 187, pp. 128-138

  4. Niraparib Population Pharmacokinetics and Exposure-Response Relationships in Patients With Newly Diagnosed Advanced Ovarian Cancer

    Clinical Therapeutics, Vol. 46, Núm. 8, pp. 612-621

  5. Patterns of initial ovarian cancer recurrence on niraparib maintenance monotherapy in patients with no baseline evidence of disease after first-line chemotherapy: An ad hoc subgroup analysis of PRIMA/ENGOT-OV26/GOG-3012

    Gynecologic Oncology, Vol. 189, pp. 68-74

  6. Predictors of long-term progression-free survival in patients with ovarian cancer treated with niraparib in the PRIMA/ENGOT-OV26/GOG-3012 study

    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, Vol. 34, Núm. 7, pp. 1041-1050

  7. Stroke in critically ill patients with respiratory failure due to COVID-19: Disparities between low-middle and high-income countries

    Heart and Lung, Vol. 68, pp. 131-144

2023

  1. Ceramide synthase 6 (CerS6) is upregulated in alcohol-associated liver disease and exhibits sex-based differences in the regulation of energy homeostasis and lipid droplet accumulation

    Molecular Metabolism, Vol. 78

  2. Long-term safety of spinal cord stimulation systems in a prospective, global registry of patients with chronic pain

    Pain Management, Vol. 13, Núm. 2, pp. 115-127

  3. Progression-free survival and safety at 3.5 years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer

    European Journal of Cancer, Vol. 189

  4. Prospective evaluation of the tolerability and efficacy of niraparib dosing based on baseline body weight and platelet count: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial

    Cancer, Vol. 129, Núm. 12, pp. 1846-1855

2022

  1. Early short course of neuromuscular blocking agents in patients with COVID-19 ARDS: a propensity score analysis

    Critical Care, Vol. 26, Núm. 1

  2. Impact of disease progression on health-related quality of life of advanced ovarian cancer patients – Pooled analysis from the PRIMA trial

    Gynecologic Oncology, Vol. 166, Núm. 3, pp. 494-502

2021

  1. A Comparative Study of Sex Distribution, Autoimmunity, Blood, and Inflammatory Parameters in Chronic Spontaneous Urticaria with Angioedema and Chronic Histaminergic Angioedema

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 9, Núm. 6, pp. 2284-2292

  2. Add-on cannabidiol in patients with Dravet syndrome: Results of a long-term open-label extension trial

    Epilepsia, Vol. 62, Núm. 10, pp. 2505-2517

  3. Considerations for treatment duration in responders to immune checkpoint inhibitors

    Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 3

  4. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

2020

  1. Niraparib in Patients With Newly Diagnosed Advanced Ovarian Cancer

    Obstetrical and Gynecological Survey

2019

  1. Niraparib in patients with newly diagnosed advanced ovarian cancer

    New England Journal of Medicine, Vol. 381, Núm. 25, pp. 2391-2402

2018

  1. Perspectives in immunotherapy: Meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy)

    Journal for ImmunoTherapy of Cancer, Vol. 6, Núm. 1